Ali S. Razai is a litigation partner in our Orange County office.
Mr. Razai has a broad intellectual property litigation practice, having handled cases involving utility patents, design patents, trademarks, trade dress, copyrights, trade secrets, false advertising, unfair competition and breach of contract throughout California and nationwide.
He has worked on a diverse range of matters involving mechanical devices, optics, medical devices, biotechnology and pharmaceuticals. Mr. Razai has handled matters for a diverse array of clients, including Oakley, Mexicana Airlines, 99¢ Only Stores, Ranbaxy Pharmaceuticals, Ligand Pharmaceuticals, and I-Flow Corporation (a subsidiary of Kimberly-Clark).
Mr. Razai is a registered patent attorney and also has extensive experience in patent prosecution, having obtained numerous patents for clients in various technology areas, particularly biotechnology. Mr. Razai has also worked within the AgBio industry, working on patents involving carbon scrubbing exhaust through algae and using the algae as green energy. Additionally, he has worked on an internet domain name litigation matter.
Mr. Razai was seconded by the firm to act as interim in-house patent counsel at Oakley, Inc. for an extended period, during which Mr. Razai handled all of Oakley's patent matters, including prosecution, litigation and due diligence.
Prior to joining the firm, Mr. Razai was a Research Associate at the UCLA AIDS Institute studying the effect of the HIV virus on cytokine expression. After receiving his Masters in Public Health from Berkeley in 2001, he went to UCSF where he focused his research on the development of therapeutic antibodies against the neurotoxin produced by the bio-terror agent C. botulinum. Mr. Razai's work at UCSF resulted in multiple royalty-bearing patents for a cure to botulism.
- Named a “Leading Litigator – IP Litigation” in the 2022 edition of Lawdragon’s “500 Leading Litigators in America” guide
- Recognized by The Legal 500 "United States" for Patent Litigation (2021 - 2022) and Trademark Litigation (2022)
- Named a 2022 "Life Science Star" for Patent Litigation in the Legal Media Group's (LMG) "LMG Life Sciences" Guide
- Recognized in the World Trademark Review (WTR) 1000 as a "Leading Trademark Lawyer" (2020 - 2022). The 2022 guide celebrated Razai as a "powerfully effective litigator", who is "great at mediation, strategically smart and well-recognized at running large and small cases." In the 2021 guide, he was described as a "seasoned" and "winning" litigator through all phases, as well as a "backbone of the litigation practice." In the 2020 guide, he was described as a client as "proactive in getting to know your business well before the first case arises...he knows his way around the courtroom and understands the personalities of the neutrals well".
- Named a 2015 and 2016 "Southern California Rising Star" by Super Lawyers magazine for his work in intellectual property litigation
- Recognized in the Los Angeles magazine as one of Southern California's "Rising Stars" in a survey of his peers (2015).
Razai A, et. al., Molecular Evolution Of Antibody Affinity For Sensitive Detection Of Botulinum Neurotoxin Type A. J Mol Biol. 2005 Aug 5;351(1):158-69.
Koka PS, Brooks DG, Razai A, Kitchen CM, Zack JA., HIV Type 1 Infection Alters Cytokine mRNA Expression In Thymus. AIDS Res. & Hum. Retroviruses. 2003 Jan 1;19(1):1-12.
PMID: 12581511 [PubMed - indexed for MEDLINE
Speeches & Seminars
Bayside Chat – IP Issues and Trends in a Pandemic and (Eventually) Post-Pandemic World, ACC DoubleHeader (October 2021)
Panelist, "Defensive Litigation Strategy," Orange County IP Strategy Summit (2016).
Speaker, "Enforcing Your Design Patents," IP Impact - Silicon Valley (2014).
Speaker, "Intellectual Property Enforcement," OCBA - Corporate Counsel Section (2014).
Speaker, "Intellectual Property Law Primer," Iranian American Bar Association (2009).